Search Results
Your search for The ASCO matches 21137 pages
Showing 1751 - 1800Breast Cancer 2022–2023 Almanac
The past year has been an exciting time for breast oncologists and patients with all stages of breast cancer, with new agents approved and long-term results from pivotal trials showing improved survival for patients with metastatic disease. Let’s take a look at some of the highlights in early-stage ...
Recent FDA Approvals in Breast Cancer
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and expanded indications for older therapeutic agents used in breast cancer. Abemaciclib Plus Endocrine Therapy On March 3, 2023, the FDA expanded the indication for abemaciclib with endocrine...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...
EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer in the ...
Expert Point of View: Nancy Chan, MD
Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investigated the addition of adjuvant abemaciclib (an oral CDK4/6 inhibitor) to endocrine therapy in a...
Expert Point of View: Ines Vaz-Luis, MD, PhD
The invited discussant of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, Ines Vaz-Luis, MD, PhD, of the Breast Cancer Survivorship Group, Gustave Roussy, Villejuif, France, pointed out that the benefit of ovarian suppression or ablation in reducing breast cancer...
EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
PET Imaging May Validate Use of Antibody-Drug Conjugates Plus Lovastatin to Enhance HER2-Targeted Cancer Therapy
Monitored by immune positron-emission tomography (PET) imaging, a novel therapeutic approach combining HER2-targeted therapies with the lipid-lowering drug lovastatin may reduce the number of cancer treatments required to prevent tumor growth, according to a recent study published by Brown et al in ...
Tumor Debulking Plus Palliative Chemotherapy May Not Impact Quality of Life in Patients With Metastatic Colorectal Cancer
Intensive local-regional tumor debulking in addition to standard palliative chemotherapy may not impact the overall quality of life of patients with metastatic colorectal cancer, according to a novel study published by Bakkerus et al in JNCCN–Journal of the National Comprehensive Cancer Network....
FDA Approves Adjuvant Nivolumab for Stage IIB/IIC Melanoma
On October 13, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage IIB or IIC melanoma in patients aged 12 years and older. CheckMate 76K Efficacy was evaluated in CheckMate 76K (ClinicalTrials.gov identifier NCT04099251),...
ASCO Launches New Webinar: Making Palliative Care a Part of Your Oncology Practice
ASCO President Lynn Schuchter, MD, FASCO, has made access to palliative and supportive care among patients with cancer a central focus of her presidential term. Although not all cancer clinicians can be palliative care specialists, because palliative and supportive care are so essential to every...
How War Has Disrupted the Management of Patients With Breast Cancer in Sudan
Sudan is the third-largest country in Africa, spanning 1,886,068 km2. It is situated in an area surrounded by North Africa, Sub-Saharan Africa, and the Middle East. As of 2020, Sudan had a population of approximately 43.8 million people, with a significant proportion being younger than age 15....
Expert Point of View: Michail Ignatiadis, MD, PhD and Stephen R.D. Johnston, MD, PhD
The September 2023 European Society for Medical Oncology (ESMO) Virtual Plenary presentation of the NATALEE health-related quality-of-life (QOL) findings was discussed by Michail Ignatiadis, MD, PhD, and Stephen R.D. Johnston, MD, PhD. Dr. Ignatiadis is Director of the Breast Medical Oncology...
NATALEE Trial: Quality of Life Maintained for Many Patients Treated With Ribociclib for Early-Stage Breast Cancer
An analysis of patient-reported outcomes in the adjuvant phase III NATALEE trial of ribociclib plus endocrine therapy in early-stage breast cancer showed maintenance of health-related quality of life (QOL), as determined by a number of factors. For patients receiving the inhibitor of...
Patients With Cancer May Be Interested in Complementary Therapies, Survey Says
Researchers have found that patients and oncologists may be supportive of complementary therapies for cancer treatment, according to a new survey conducted on behalf of the Healing Works Foundation. However, the findings also indicated there may be a disconnect between the growing interest in...
AI Software Demonstrates Potential to Accurately Detect Skin Cancer
A novel artificial intelligence (AI) software may be effective in detecting skin cancer and precancerous lesions, according to findings presented by Andrew et al at the European Academy of Dermatology and Venereology Congress 2023. Background Skin cancer detection using AI software has rapidly...
Chemical Hair Relaxers May Increase Risk of Uterine Cancer Among Black Women
Researchers have found that long-term use of chemical hair relaxers may be associated with an increased risk of uterine cancer in postmenopausal Black women, according to a recent study published by Bertrand et al in Environmental Research. Background Chemical hair relaxers are heavily marketed to...
Nonmelanoma Skin Cancers May Have Higher Mortality Rate Than Melanoma
Nonmelanoma skin cancer may be causing a greater number of global deaths than melanoma, according to findings presented by Salah et al at the European Academy of Dermatology and Venerology Congress 2023. Investigators also suggested that nonmelanoma skin cancer may be underreported and that the...
FDA Approves Encorafenib With Binimetinib for Metastatic BRAF V600E–Mutated NSCLC
On October 11, the U.S. Food and Drug Administration (FDA) approved the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) for adult patients with metastatic non–small cell lung cancer (NSCLC) and a BRAF V600E mutation, as detected by an FDA-approved test. The FDA...
FDA Grants Marketing Authorization to Edison Histotripsy System for Treatment of Liver Tumors
On October 9, HistoSonics, the manufacturer of the Edison System and novel histotripsy therapy platforms, announced the marketing authorization of its platform via the U.S. Food and Drug Administration's (FDA) De Novo Classification Request process, a rigorous premarket review pathway for medical...
Investigators Compare Health Information Exchange Data With Patient Self-Reported Data to Measure Cancer Screening Uptake
Investigators have determined that knowing which patient populations are following cancer screening guidelines may be beneficial to public health officials, policymakers, and researchers developing strategies to improve screening adherence, according to a recent study published by Bhattacharyya et...
Children of Young Female Patients With a History of Cancer May Be at Risk of Birth Defects
The children of adolescent and young adult female patients with a history of cancer may face a higher risk of birth defects, according to a recent study published by Murphy et al in Cancer Epidemiology, Biomarkers & Prevention. Background “Concerns like the health of future children are at the ...
Guideline Update Reflects Recent Surge of New Data in Systemic Therapy for Melanoma
A guideline update on systemic treatment for melanoma offers new guidance in several areas, including the selection of front-line therapy for patients with metastatic disease with and without BRAF mutations, treatment of patients with earlier-stage disease in the adjuvant setting, and emerging...
ASCO and State Affiliates Wrap Up Successful State Sessions
After a fast-paced first half of the year, most state legislatures across the 50 states and Washington, DC, have adjourned for the year. The Association for Clinical Oncology (ASCO) and State Affiliates successfully collaborated to advance many shared 2023 state advocacy priorities, including those ...
Expert Point of View: Gentry King, MD
Gentry King, MD, Assistant Professor in the Division of Hematology and Oncology, University of Washington, and Assistant Professor in the Clinical Research Division of Fred Hutchinson Cancer Center, Seattle, offered his thoughts on the findings of NuTide:121. “Only recently, with TOPAZ-1...
Tracking the Progress Being Made in the Treatment of Breast Cancer and the Challenges Ahead
Jame Abraham, MD, FACP, has been in the field of oncology for more than 2 decades, he and says this is both one of the most exhilarating and challenging times in cancer care. “What excites me the most are the innovations in treatment that are literally transforming the lives of our patients and...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
Do Patients With Advanced Cancer Value Quality Over Quantity of Life?
A recent study published by Yong et al in Value in Health may help clarify the intricate interplay between the quality-of-life and survival preferences of patients with advanced cancer. Limited access to palliative care services may contribute to suffering, particularly among patients with cancer...
Adjuvant Pembrolizumab May Offer Survival Benefit Over Observation in Patients With Muscle-Invasive or Locally Advanced Urothelial Carcinoma
The Alliance Data and Safety Monitoring Board has determined that adjuvant pembrolizumab may improve disease-free survival in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma, according to the Alliance for Clinical Trials in Oncology. ...
KRAS G12C Inhibitors: Durability of Response, Efficacy in Combination, in NSCLC
At the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, the benefit of two KRAS G12C inhibitors in advanced non–small cell lung cancer (NSCLC) was upheld by the 2-year follow-up analysis of adagrasib in the KRYSTAL-11 and the early-phase CodeBreaK 101...
Chemotherapy Shortages Ongoing, According to New Survey
The National Comprehensive Cancer Network® (NCCN®) has released a follow-up survey on the ongoing chemotherapy shortages, refreshing findings they originally shared in June 2023. According to their results, 72% of the cancer centers surveyed continue to experience a shortage of carboplatin, and 59% ...
Neighborhood Walkability and Risk of Obesity-Related Cancers
Residing in more walkable neighborhoods could protect against the risk of overall obesity-related cancers in female patients, according to a recent study published by India-Aldana et al in Environmental Health Perspectives. Background Obesity has previously been linked to an increased risk of...
A Diagnosis of Ewing Sarcoma Altered the Trajectory of My Life
In August 2014, just a few weeks after my 15th birthday, my body began sending me a lot of worrisome signals that life as I knew it would soon be over. The year before, I had developed a hematoma in my right femur, which was resolved with surgery. But now the pain I was experiencing in that leg was ...
Psilocybin
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...
National Inventors Hall of Fame Recognizes Jennifer Doudna, PhD; Emmanuelle Charpentier, PhD; and Angela Hartley Brodie, PhD
The National Inventors Hall of Fame (NIHF) recognizes the enduring legacies of exceptional U.S. patent holders on an annual basis. On October 26, 2023, three female inductees will be recognized for their extraordinary contributions to cancer care and clinical research. Biochemist Jennifer...
Circulating Tumor DNA Identified in Breast Milk From Women With Breast Cancer: First Results Published
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum contains circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in...
New Poll Weighs Necessity of Life Expectancy in Cancer Screening Guidelines
A majority of older adults may disagree with the idea of using life expectancy as part of cancer screening guidelines, according to a new University of Michigan National Poll on Healthy Aging. Background The response goes against a trend in guidelines aimed at helping health-care providers decide...
Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update
Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell,...
Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this...
Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability
Ilias Houda, MD, PhD Candidate, of Amsterdam University Medical Centers, discusses the differing opinions of thoracic surgeons when it comes to resection for stage III non–small cell lung cancer (NSCLC). The international EORTC survey showed there is no consensus, although respondents were more...
Seshiru Nakazawa, MD, PhD, on NSCLC and Point Mutations as de Novo Oncogenic Drivers
Seshiru Nakazawa, MD, PhD, of Dana-Farber Cancer Institute, discusses activating the MET tyrosine kinase domain mutation, which has been identified as the sole oncogenic mutation in a small but significant subset of patients with non–small cell lung cancer (NSCLC). According to Dr. Nakazawa’s...
Shirish M. Gadgeel, MD, on Pembrolizumab Plus Chemotherapy for Metastatic NSCLC: 5-Year Follow-up
Shirish M. Gadgeel, MD, of the Henry Ford Cancer Institute, discusses a 5-year follow-up study of patients with metastatic non–small cell lung cancer (NSCLC) who were treated with pembrolizumab plus chemotherapy. According to Dr. Gadgeel, the findings continue to support the use of pembrolizumab...
Diabetes May Be Linked to Lower Survival Among Patients With Multiple Myeloma; Survival Outcomes May Be Race-Dependent
Patients with multiple myeloma who also have diabetes may experience worse overall survival outcomes compared with patients who don’t have diabetes, according to a recent study published by Shah et al in Blood Advances. The new findings demonstrated that the differences in survival may be dependent ...
Liquid Biopsy May Help Identify Patients With NSCLC Who Could Benefit From Radiation Therapy
Liquid biopsy may help determine which patients with oligometastatic non–small cell lung cancer (NSCLC) with metastases may be most likely to benefit from targeted, high-dose radiation therapy rather than drug-based therapy, according to findings simultaneously published by Semenkovich et al in npj ...
Racial and Ethnic Minority Patients With Breast Cancer May Be Less Likely to Receive Palliative Care Than White Patients
Despite a steady increase in palliative care utilization from 2004 to 2020, racial and ethnic minority patients with metastatic breast cancer may be less likely to receive palliative care compared with non-Hispanic White patients with the disease, according to new findings presented by Freeman et...
Using Recent Diagnostic Scans May Cut Time to Treatment for Patients Needing Urgent Palliative Radiotherapy
Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments may substantially reduce the time spent waiting for urgent treatment, improving the patient experience, a new study suggests. Patients who may benefit from ...
Sexual Activity and Vaginal Dilation Associated With Fewer Side Effects After Chemoradiation for Cervical Cancer
People who engage in sexual activity or vaginal dilation after chemoradiation for cervical cancer are at lower risk for long-term side effects, according to a new study from researchers in Austria. Findings of the EMBRACE study were presented by Kirchheiner et al at the 2023 American Society for...
The New Era of Perioperative Therapy in Non–Small Cell Lung Cancer
Recent developments in surgery and therapeutics are changing the perioperative approach to non–small cell lung cancer (NSCLC). These advances were discussed at the 2023 Debates and Didactics in Hematology and Oncology conference, sponsored by Emory University, by Jennifer W. Carlisle, MD, Assistant ...
Hypofractionated Radiotherapy May Reduce Burden of Head and Neck Cancer in Low- and Middle-Income Countries
Fewer and higher doses of radiation may be effective at treating patients with head and neck squamous cell carcinoma, according to new findings presented by Bentzen et al at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 02). Background Head and neck squamous...
